mannitol fresenius 15% infusioonilahus
fresenius kabi polska sp. z o.o. - mannitool - infusioonilahus - 15% 500ml 12tk; 15% 500ml 1tk
mannitol fresenius 10% infusioonilahus
fresenius kabi polska sp. z o.o. - mannitool - infusioonilahus - 10% 500ml 1tk; 10% 500ml 12tk
prepandrix
glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) sarnane tüvi (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaktsiinid - aktiivne immuniseerimine gripiviiruse h5n1 alatüübi vastu. see näidustus põhineb immunogenicity andmeid tervisliku teemasid, alates vanusest 18 aastat aastast pärast manustamist kaks annust vaktsiini, mis on valmistatud alatüübi h5n1 tüve. prepandrix tuleks kasutada vastavalt euroopa liidu arendus.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastilised ained - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
pumarix
glaxosmithkline biologicals s.a. - pandeemilise gripi vaktsiin (h5n1) (split virion, inaktiveeritud, adjuvanted) - influenza, human; immunization; disease outbreaks - vaktsiinid - gripi profülaktika ametlikult pandeemia korral. pandeemia-gripi vaktsiini tuleb kasutada vastavalt euroopa liidu arendus.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastilised ained - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
poleposition® ja mirador® segu
adama - emulsioonikontsentraat / suspensioonikontsentraat - asoksüstrobiin + protiokonasool - fungitsiidid
kantik®
adama - emulsioonikontsentraat - fenpropidiin + prokloraas + tebukonasool - fungitsiidid
mirador® forte
adama - emulsioonikontsentraat - asoksüstrobiin + tebukonasool - fungitsiidid
tomahawk® 200 ec
adama - emulsioonikontsentraat - fluroksüpüür - herbitsiidid